» Authors » David A Brenner

David A Brenner

Explore the profile of David A Brenner including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 279
Citations 23369
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
21.
Gao H, Jin Z, Bandyopadhyay G, Wang G, Zhang D, Cunha E Rocha K, et al.
Cell Metab . 2022 Aug; 34(8):1201-1213.e5. PMID: 35921818
Hepatocytes have important roles in liver iron homeostasis, abnormalities in which are tightly associated with liver steatosis and fibrosis. Here, we show that non-alcoholic fatty liver disease (NAFLD) and steatohepatitis...
22.
Gao H, Jin Z, Bandyopadhyay G, Cunha E Rocha K, Liu X, Zhao H, et al.
Cell Metab . 2022 Jun; 34(7):978-990.e4. PMID: 35700738
Nonalcoholic steatohepatitis (NASH) is a liver disease associated with significant morbidity. Kupffer cells (KCs) produce endogenous miR-690 and, via exosome secretion, shuttle this miRNA to other liver cells, such as...
23.
Duan Y, Chu H, Brandl K, Jiang L, Zeng S, Meshgin N, et al.
Nat Commun . 2021 Dec; 12(1):7172. PMID: 34887405
Complement receptor of immunoglobulin superfamily (CRIg) is expressed on liver macrophages and directly binds complement component C3b or Gram-positive bacteria to mediate phagocytosis. CRIg plays important roles in several immune-mediated...
24.
Rady B, Nishio T, Dhar D, Liu X, Erion M, Kisseleva T, et al.
PLoS One . 2021 Dec; 16(12):e0260721. PMID: 34879108
Non-alcoholic steatohepatitis (NASH) results, in part, from the interaction of metabolic derangements with predisposing genetic variants, leading to liver-related complications and mortality. The strongest genetic determinant is a highly prevalent...
25.
Nishio T, Koyama Y, Liu X, Rosenthal S, Yamamoto G, Fuji H, et al.
Proc Natl Acad Sci U S A . 2021 Jul; 118(29). PMID: 34253615
We investigated the role of mesothelin (Msln) and thymocyte differentiation antigen 1 (Thy1) in the activation of fibroblasts across multiple organs and demonstrated that Msln mice are protected from cholestatic...
26.
Ramirez-Perez F, Woodford M, Morales-Quinones M, Grunewald Z, Cabral-Amador F, Yoshida T, et al.
Am J Physiol Heart Circ Physiol . 2021 Jul; 321(2):H435-H445. PMID: 34242094
Arterial stiffening, a characteristic feature of obesity and type 2 diabetes, contributes to the development and progression of cardiovascular diseases (CVD). Currently, no effective prophylaxis or therapeutics is available to...
27.
Baglieri J, Zhang C, Liang S, Liu X, Nishio T, Rosenthal S, et al.
Am J Pathol . 2021 Jun; 191(9):1564-1579. PMID: 34119473
Although hepatocellular cancer (HCC) usually occurs in the setting of liver fibrosis, the causal relationship between liver fibrosis and HCC is unclear. in vivo and in vitro models of HCC...
28.
Ganguly S, Muench G, Shang L, Rosenthal S, Rahman G, Wang R, et al.
Cell Mol Gastroenterol Hepatol . 2021 Jun; 12(3):891-920. PMID: 34062281
Background & Aims: How benign liver steatosis progresses to nonalcoholic steatohepatitis (NASH), fibrosis, and hepatocellular carcinoma (HCC) remains elusive. NASH progression entails diverse pathogenic mechanisms and relies on complex cross-talk...
29.
Zhou R, Llorente C, Cao J, Zaramela L, Zeng S, Gao B, et al.
Cell Mol Gastroenterol Hepatol . 2021 Feb; 12(1):293-320. PMID: 33631374
Background & Aims: Fucosyltransferase 2 (Fut2)-mediated intestinal α1- 2-fucosylation is important for host-microbe interactions and has been associated with several diseases, but its role in obesity and hepatic steatohepatitis is...
30.
Rosenthal S, Liu X, Ganguly S, Dhar D, Pasillas M, Ricciardelli E, et al.
Hepatology . 2021 Feb; 74(2):667-685. PMID: 33550587
Background And Aims: In clinical and experimental NASH, the origin of the scar-forming myofibroblast is the HSC. We used foz/foz mice on a Western diet to characterize in detail the...